Xspray Pharma Abpublis A Swedish Pharmaceutical Company Dedicated To Developing Enhanced Versions Of Protein Kinase Inhibitorspkisfor Targeted Cancer Therapiesutilizing Its Patented Hynap Technologyxspray Pharma Addresses Challenges Like Low Solubility And Variability In Drug Uptakewhich Can Affect Treatment Effectiveness And Patient Quality Of Life The Company S Strategy Centers On Creating Best In Class Drug Products By Developing Amorphous Forms Of Pkisthis Approach Allows Xspray Pharma To Market These Products After The Original Drug Patents Expireproviding A Competitive Edge In The Cancer Treatment Markettheir Lead Product Candidatedasynocdasatinib Is Expected To Launch In The U Sin 2025Offering Benefits Such As Ph Insensitivityconsistent Drug Uptakeand Lower Dosage Requirementsanother Candidatexs003Is Also In Development With Plans For Market Approval Submission In Early 2025Xspray Pharma Is Committed To Enhancing Patient Outcomes Through Innovative Drug Formulations And Is Actively Involved In Financial Reporting And Operational Updates As A Publicly Traded Company
No conferences found for this company.
| Company Name | Xspray Microparticles Ab |
| Country |
Sweden
|
| Address | N/A |
| Telephone | N/A |
| N/A |
